blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3858376

EP3858376 - DYSTROPHIN GENE EXON DELETION USING ENGINEERED NUCLEASES [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  27.06.2025
Database last updated on 11.04.2026
FormerGrant of patent is intended
Status updated on  18.02.2025
FormerExamination is in progress
Status updated on  04.02.2025
FormerGrant of patent is intended
Status updated on  07.10.2024
FormerExamination is in progress
Status updated on  27.05.2022
FormerRequest for examination was made
Status updated on  04.02.2022
FormerThe application has been published
Status updated on  02.07.2021
Most recent event   Tooltip10.04.2026Lapse of the patent in a contracting state
New state(s): SM		published on 13.05.2026 [2026/20]
Applicant(s)For all designated states
Precision Biosciences, Inc.
302 East Pettigrew Street
Dibrell Building, Suite A-100
Durham, NC 27701 / US
[2021/31]
Inventor(s)01 / JANTZ, Derek
1011 Gloria Avenue
Durham, NC North Carolina 27701 / US
02 / SMITH, James Jefferson
1916 Weaver Forest Way
Morrisville, NC North Carolina 27560 / US
03 / NICHOLSON, Michael G.
1200 Willow Drive
Chapel Hill, NC North Carolina 27517 / US
 [2021/31]
Representative(s)Grund, Martin
Grund Intellectual Property Group
Patentanwälte und Solicitor PartG mbB
Steinsdorfstraße 2
80538 München / DE
[2025/31]
Former [2021/31]Grund, Martin
Grund Intellectual Property Group
Patentanwalt und Solicitor PartG mbB
Postfach 44 05 16
80754 München / DE
Application number, filing date20189872.312.03.2015
[2021/31]
Priority number, dateUS201461951648P12.03.2014         Original published format: US 201461951648 P
[2021/31]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3858376
Date:04.08.2021
Language:EN
[2021/31]
Type: B1 Patent specification 
No.:EP3858376
Date:30.07.2025
Language:EN
[2025/31]
Search report(s)(Supplementary) European search report - dispatched on:EP06.07.2021
ClassificationIPC:A61K38/46, A61K38/54, C07K14/47, C12N15/00, C12N9/22, C12N7/00, A61P21/00, A61P21/04, A61P43/00, A61K48/00
[2021/31]
CPC:
A61K38/465 (EP,US); A61K38/54 (EP,US); A61K48/005 (EP);
A61P21/00 (EP); A61P21/04 (EP); A61P43/00 (EP);
C07K14/4708 (EP); C12N7/00 (US); C12N9/22 (EP,US);
C12N2750/14143 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/10]  
Former [2021/31]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:DYSTROPHINGENEXONDELETION MIT MANIPULIERTEN NUKLEASEN[2021/31]
English:DYSTROPHIN GENE EXON DELETION USING ENGINEERED NUCLEASES[2021/31]
French:DÉLÉTION D'EXON DU GÈNE CODANT LA DYSTROPHINE AU MOYEN DE NUCLÉASES GÉNÉTIQUEMENT MODIFIÉES[2021/31]
Examination procedure01.02.2022Amendment by applicant (claims and/or description)
01.02.2022Examination requested  [2022/10]
01.02.2022Date on which the examining division has become responsible
30.05.2022Despatch of a communication from the examining division (Time limit: M06)
29.11.2022Reply to a communication from the examining division
15.02.2023Despatch of a communication from the examining division (Time limit: M06)
24.08.2023Reply to a communication from the examining division
26.10.2023Despatch of a communication from the examining division (Time limit: M06)
23.04.2024Reply to a communication from the examining division
08.10.2024Communication of intention to grant the patent
04.02.2025Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
19.02.2025Communication of intention to grant the patent
20.06.2025Fee for grant paid
20.06.2025Fee for publishing/printing paid
20.06.2025Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP15761320.9  / EP3116533
Divisional application(s)EP25191909.8  / EP4659765
Fees paidRenewal fee
23.11.2020Renewal fee patent year 03
23.11.2020Renewal fee patent year 04
23.11.2020Renewal fee patent year 05
23.11.2020Renewal fee patent year 06
31.03.2021Renewal fee patent year 07
29.03.2022Renewal fee patent year 08
29.03.2023Renewal fee patent year 09
21.03.2024Renewal fee patent year 10
27.03.2025Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHR30.07.2025
PL30.07.2025
SM30.07.2025
NO30.10.2025
RS30.10.2025
GR31.10.2025
IS30.11.2025
[2026/20]
Former [2026/10]HR30.07.2025
PL30.07.2025
NO30.10.2025
RS30.10.2025
GR31.10.2025
IS30.11.2025
Former [2026/09]HR30.07.2025
NO30.10.2025
GR31.10.2025
IS30.11.2025
Former [2026/08]HR30.07.2025
NO30.10.2025
IS30.11.2025
Former [2026/07]IS30.11.2025
Documents cited:Search[A] WO2013163628  (UNIV DUKE et al.)
 [A] CA2878654  (ASS FR CONTRE LES MYOPATHIES et al.)
 [A] US2013337454  (DUCHATEAU PHILIPPE et al.)
 [AD] WO2014197748  (UNIV DUKE et al.)
 [A] WO2014071219  (FACTOR BIOSCIENCE INC et al.) [A] 1-8 * claim - *
 [AP] WO2017072590  (CRISPR THERAPEUTICS AG et al.) [AP] 1-8 * figure -; claim - *
 [AP] WO2011040885  (UNIV SINGAPORE et al.) [AP] 1-8 * figure -; claim - *
 [T] WO2009101399  (ISIS INNOVATION et al.)
 [AD]   DAVID G OUSTEROUT ET AL: "Reading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients", MOLECULAR THERAPY, vol. 21, no. 9, 4 June 2013 (2013-06-04), pages 1718 - 1726, XP055184655, ISSN: 1525-0016, DOI: 10.1038/mt.2013.111

DOI:   http://dx.doi.org/10.1038/mt.2013.111
 [A]   AURLIE NICOLAS ET AL: "Assessment of the structural and functional impact of in-frame mutations of the DMD gene, using the tools included in the eDystrophin online database", ORPHANET JOURNAL OF RARE DISEASES, BIOMED CENTRAL LTD, LO, vol. 7, no. 1, 9 July 2012 (2012-07-09), pages 45, XP021116911, ISSN: 1750-1172, DOI: 10.1186/1750-1172-7-45

DOI:   http://dx.doi.org/10.1186/1750-1172-7-45
 [A]   TABEBORDBAR MOHAMMADSHARIF ET AL: "In vivo gene editing in dystrophic mouse muscle and muscle stem cells", SCIENCE (WASHINGTON D C), vol. 351, no. 6271, 22 January 2016 (2016-01-22), pages 407 - 411, XP002775107

DOI:   http://dx.doi.org/10.1126/science.aad5177
 [A]   MAGGIO IGNAZIO ET AL: "Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations", NUCLEIC ACIDS RESEARCH, vol. 44, no. 3, 18 February 2016 (2016-02-18), pages 1449 - 1470, XP002775108 [A] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.1093/nar/gkv1540
ExaminationEP2483427
   NICOLAS TURENNE ET AL: "Analyse de donnes textuelles sous R", 1 January 2016 (2016-01-01), XP055418886, Retrieved from the Internet
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.